Molecular Biometrics has established research and development facilities in both Canada and the United States.

Molecular Biometrics Canada (MB Canada) was founded in in Montreal in April 2007 as the company’s primary R&D facility and is responsible for developing Molecular Biometrics’ lead product candidate, ViaMetrics-E™. With expertise in biotechnology engineering, analytical chemistry, and cell biology, MB Canada has advanced the company’s technology platform into diagnostic and therapeutic tools. With a thorough knowledge of spectroscopy and instrument design, scientists at MB Canada are generating innovative ideas in the metabolomic analysis of biological fluids, and refining methodologies to analyze metabolomic profiles. Under the direction of Dr. Hyman Schipper, Medical Director, MB Canada plans to expand its research into the study of neurodegenerative disease.

Molecular Biometrics’ U.S. research and development facility, located in New Haven, Connecticut, is led by Dr. Denny Sakkas, an internationally recognized and renowned embryologist. Established in January 2008, the company’s New Haven facility is the headquarters for all R&D activities in the field of reproductive medicine and infertility. Specifically, the New Haven facility tests and develops applications of the company’s novel technology platform for use in the Assissted Reproductive Technologies. Further clinical development will be conducted in the assessment of gamete reproductive potential, and testing the affects of cryopreservation and genetic screening using MB’s technology platform of biospectroscopy based metabolomics.

Montreal, Quebec, Canada

Director of Operations, Canada

Vincent Dodelet earned his Bachelor of Science and Doctorate degrees in microbiology and immunology from McGill University. He completed a post-doctoral fellowship at the Burnham Institute (La Jolla, CA) and recently obtained his MBA (bioindustry specialization) from the Université du Québec à Montréal. Dr. Dodelet comes to Molecular Biometrics from the Office of Technology Transfer at McGill University, where he served as life sciences officer. There, he was responsible for intellectual property management and business development for a portfolio of life science technologies. Previously, Dr. Dodelet held senior research positions at two Montreal biotechnology companies and a large-scale Genome Canada funded program. Dr. Dodelet is Director of Operations and development at Molecular Biometrics Canada, where he oversees the R&D activities, the intellectual property portfolio and the general administration.

Associate Director, R&D

K. Pieter Roos earned his Doctorate degree in analytical chemistry at Concordia University and completed a post-doctoral fellowship at McGill University. Previously, he worked as a senior scientist at IatroQuest coorperation, where he was primarily involved in bio-sensor development. Dr. Roos also held a consulting position for both ID Biomedical and Aegera cooperation in assay development for pharmaceuticals. Dr Roos is an Associate Director of research and development at Molecular Biometrics Canada and is responsible for the development and design of Molecular Biometrics’ instrumentation and analytical technologies.

Research Scientist

Lucy L. Botros earned both her Bachelor of Science and her Master of Science degrees in analytical chemistry at McGill University. There she was trained in the application of chemometrics to NMR spectroscopic analyses of biological fluids. Ms. Botros is a Research Scientist for Molecular Biometrics Canada and is primarily responsible for research conducted within the Reproductive Health & Infertility therapeutic area. She focuses on the measurement and chemometric analysis of metabolomic profiles generated from embryo culture media, oocyte culture media, and seminal plasma.

Marketing Associate

Kristin earned her Bachelor of Science and Bachelor of Technology degrees at Cape Breton University and continued to graduate school earning a Master of Science degree in analytical chemistry at McGill University. Her master’s thesis involved the analysis of amniotic fluid with near infrared and Raman spectroscopy. Ms. Power was previously employed by SiliCycle Inc. as a technical sales representative for New England, Western US, and Canada. She is a Marketing Associate for Molecular Biometrics Canada, coordinating marketing and communications efforts and also does research in the maternal fetal medicine and neurodegenerative therapeutic areas. Kristin is also the webmaster for www.molecularbiometrics.com.

New Haven, Connecticut, USA

Chief Scientific Officer

Senior Research Scientist

Mark J. Henson earned his Bachelor of Arts degree in chemistry (with ACS certification) from Kalamazoo College. He later earned his Doctorate degree in inorganic chemistry from Stanford University, where his work focused on applications of Raman spectroscopy in studying mechanisms of dioxygen cleavage in coupled binuclear and trinuclear copper models of enzyme active sites. Dr. Henson previously held a position as supervisor of the process and optical spectroscopy technology laboratory and analytical R&D department at Pfizer, Inc. Dr Henson is a Senior Research Scientist at Molecular Biometrics and is also responsible for the development and design of analytical technologies and clinical studies.

Research Scientist

Kevin D. Judge earned his Bachelor of Science degrees in chemistry and mathematics before earning his doctorate in analytical chemistry from the University of Rhode Island. His research focused heavily on chemometrics as applied to vibrational spectroscopy, in particular Mid-IR, Raman, and IR spectral imaging. Specific topics included preprocessing issues, classification models, pattern recognition using Artificial Neural Networks, and probability determination with Bayesian statistics. As a Research Scientist for Molecular biometrics, Dr. Judge has been involved in chemometric model development, spectral variable selection, instrument standardization and calibration transfer.

MB hires Denny Sakkas, PhD, renowned Yale embryologist

MB to Open Research and Development Facility in Montreal